The C-terminal third of intimin binds to its translocated receptor (Tir) to promote attaching and effacing lesion formation during infection with enteropathogenic Escherichia coli (EPEC). We observed that the adherence of EPEC strains to HEp-2 cells was reduced and that actin polymerization was blocked by antibody raised against the C-terminal third of intimin ␣.Enteropathogenic Escherichia coli (EPEC) strains are pediatric pathogens associated with acute and protracted infantile diarrhea, particularly in developing countries. Outbreaks of disease among children and adults also occur sporadically worldwide (19). EPEC strains target the small intestinal mucosa where they adhere, efface the microvilli, and induce cytoskeletal changes and pedestal formation in the underlying enterocytes. These lesions, described in 1983 by Moon et al. as attaching and effacing (A/E) lesions, are the hallmark pathology of EPEC infection (18). The bacterial surface protein intimin is necessary for A/E lesion formation and for the full virulence of EPEC in human volunteer infections (3, 4, 11). Since the carboxyl-terminal 190 amino acids of intimin bind the translocated intimin receptor, Tir (1, 15), we reasoned that antibody directed against the binding domain of intimin might block lesion formation.Intimins expressed by various E. coli strains that produce A/E lesions in humans and animals have been divided into at least five distinct types based on the antigenic variability of the 280 C-terminal amino acids that comprise the eukaryotic binding domain. Previous studies in our laboratory showed that antibody directed against the binding domain of intimin ␥ effectively reduces binding of enterohemorrhagic E. coli (EHEC) O157:H7, but not EPEC strain E2348/69, to HEp-2 cells (5). Other investigators used rabbit polyclonal antibodies against a histidine-tagged 280-amino-acid portion of the C terminus of intimin ␣ to monitor intimin expression in the HEp-2 cell EPEC adherence model (12). Here we evaluated the capacity of antibody specific for the carboxyl-terminal binding domain of EPEC intimin ␣ to interfere with the binding of EPEC strains and to block actin polymerization in the HEp-2 cell adherence assay.